Richard Levy, M.D., Incyte's Executive Vice President, Chief Drug Development and Medical Officer, added, "The updated data from the Phase II trial in myelofibrosis, our most advanced program for INCB18424, demonstrate that the dosing regimens that are being used in our Phase III trials, COMFORT-I and COMFORT-II, have the potential to be well tolerated and provide durable clinical improvement in both splenomegaly and the debilitating constitutional symptoms seen in the majority of MF patients.

COMFORT-I and II are currently enrolling patients diagnosed with myelofibrosis, either primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, regardless of the presence or absence of the JAK V617F mutation. Additionally, in both studies, patients not randomized to receive INCB18424 will have the opportunity to cross over to receive this investigational therapy.